This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hooke, M. C. Articles by Bostrom, B. Search for Related Content PubMed PubMed Citation Articles by Hooke, M. C. Articles by Bostrom, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Pain Palliative Care Hazardous Substances DB PROPOFOL Social Bookmarking                         What's this?

Propofol Use in Pediatric Patients With Severe Cancer Pain at the End of Life

Children's Hospitals and Clinics of Minnesota, Department of Hematology/Oncology, Minneapolis

Erin Grund, BS

Heather Quammen, RN, CNP

Children's Hospitals and Clinics of Minnesota, Department of Hematology/Oncology, Minneapolis

Blaine Miller, MD

Paul McCormick, MD

Department of Pediatric Anesthesia at Children's Hospitals and Clinics of Minnesota, Minneapolis

Bruce Bostrom, MD

Children's Hospitals and Clinics of Minnesota, Department of Hematology/Oncology, 2525 Chicago Ave S, Minneapolis, MN 55404; phone: (612) 813-6282; fax: (612) 813-6325; bruce.bostrom{at}childrensmn.org

This article describes the use and effectiveness of adjuvant propofol for pain control for pediatric oncology patients at the end of life. All patients experienced severe pain and agitation, not well controlled by continuous infusion opioids and benzodiazepines. Upon starting propofol, most patients had a temporary stabilization in the dose of opioids with subjective improvement in pain control, increased alertness, and improved ability to interact. Propofol infusions were continued until death in most patients. Two patients received propofol infusions at home. Subsequent increases in opioids in 6 patients and propofol in all patients were required for optimal pain control. Adverse effects included agitation in 5 patients and hallucinations in 2, which were controllable with benzodiazepines. One patient developed severe tetany, requiring propofol interruption; propofol was successfully restarted at a lower dose with an adjuvant benzodiazepine. The authors conclude that propofol is a useful and tolerable adjuvant agent for pain management in pediatric oncology patients at the end of life. It is a useful adjuvant if pain is unresponsive to continuous infusion opioids or if rapidly escalating doses of opioids are required.

Key Words: propofol • cancer pain • pediatric oncology • pain control • palliative care • end of life

Journal of Pediatric Oncology Nursing, Vol. 24, No. 1, 29-34 (2007)
DOI: 10.1177/1043454206296026


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. M. Herndon and E. Zimmerman High-Dose Propofol Drip for Palliative Sedation: A Case Report American Journal of Hospice and Palliative Medicine, January 1, 2009; 25(6): 492 - 495. [Abstract] [PDF]